Decision: Favourable
Study Title:
A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NREC Code:
22-NREC-CT-117
Decision:
Favourable
Meeting Date:
13/07/2022
Study Type:
CT Application
Principal Investigator:
Dr Anne Fortune
PI Institution:
Mater Misericordiae University Hospital
Sponsor:
Incyte Corporation